ImmuneWalk Therapeutics News
2 articles
growth-positive
ImmuneWalk Therapeutics Announces Positive Topline Phase 1 SAD Data for Immunology and Inflammation Drug Candidate IW-601
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, announced positive topline data from the single ascending dose (SAD) portion of their Phase 1 POINTGUARD study at the EULAR 2025 conference. The study evaluates IW-601, a monoclonal antibody targeting myeloid cells, demonstrating safety, tolerability, and favorable pharmacokinetics. The trial met all primary and secondary endpoints, showing IW-601s potential to modulate immune and inflammatory diseases by preventing myeloid cells from entering inflamed tissues. The company plans to continue with the multiple ascending dose (MAD) part of the study, with results expected later in 2025. IW-601s novel mechanism offers a differentiated approach compared to existing treatments, with potential applications in diseases like multiple sclerosis and rheumatoid arthritis.
Product Stage
growth-positive
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
ImmuneWalk Therapeutics, a clinical-stage biotechnology company, has completed a $7 million seed financing round with contributions from an institutional investor and its management team. The company focuses on developing therapies for immune-inflammatory diseases and is currently conducting a Phase 1 clinical trial for its lead candidate, IW-601. This monoclonal antibody targets MOSPD2, an adhesion checkpoint protein, to reduce immune-driven inflammation. The company plans to present positive data from its first-in-human trial at the EULAR 2025 Annual Meeting and BIO International Convention. The funding will help accelerate the development of IW-601 towards additional key milestones in 2025.
InvestmentProduct Stage
